Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LASP1
REST API REST API
Homo sapiens
LASP1 is differentially expressed in 293 experiments: 136 organism parts: lung, skeletal muscle, ... (134 more);, 161 disease states: normal, acute myeloid leukemia, ... (159 more);, 95 cell types 394 cell lines 30 compound treatments and 75 other conditions.
Synonyms MLN50, Lasp-1
Orthologs lasp1 (Danio rerio)   LASP1 (Gallus gallus)   LASP1_RAT (Rattus norvegicus)   Lasp1 (Mus musculus)   LASP1_BOVIN (Bos taurus)   Lasp (Drosophila melanogaster)   lasp1 (Xenopus laevis)   LASP1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cortical actin cytoskeleton, focal adhesion, protein binding, cytoskeleton, cytoplasm, ion transmembrane transporter activity, cell cortex, ion transport, metal ion binding, SH3/SH2 adaptor activity, actin filament binding, zinc ion binding, ion transmembrane transport
InterPro Term SH3_domain, Znf_LIM, SH3_2, Nebulin_35r-motif
UniProt Accession C9J9W2, Q14847, B4DGQ0, B4DIC4
Search EB-eye ENSG00000002834
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, E-GEOD-3526, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (42 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
HL-60
3
E-GEOD-96, E-MTAB-37, E-GEOD-5258
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
MOLT4
2
E-MTAB-62, E-MTAB-37
MCF-10A
2
E-TABM-420, E-GEOD-14990
388 more value(s).


Cell type

studied in E-GEOD-492, E-TABM-40, E-GEOD-22373, E-MEXP-750, E-MEXP-66, ... (48 experiments)

Factor Value U/D Experiments
monocyte
2
E-MEXP-583, E-GEOD-22373
CD8+ T cell
2
E-AFMX-5, E-GEOD-6740
stromal cell
1
2
E-GEOD-1460, E-GEOD-10797, E-MEXP-2034
endometrial tissue;vaginal tissue;myometrial tissue
1
E-MEXP-1251
secretory cell
1
E-GEOD-3998
mononuclear
1
E-GEOD-13987
89 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-MEXP-25, E-GEOD-2466, E-GEOD-1577, ... (48 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-GEOD-96, E-MTAB-62, E-GEOD-1729
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
colon carcinoma
2
E-MTAB-37, E-GEOD-3726
prostate carcinoma
1
2
E-GEOD-96, E-MTAB-62, E-MEXP-2034
Hodgkin lymphoma
1
E-MTAB-37
155 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-5741, E-TABM-782, E-GEOD-5824, ... (20 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-GEOD-3720, E-MEXP-1958
none
2
3
E-GEOD-5824, E-MEXP-1958, E-TABM-782, E-GEOD-412, E-MEXP-1389 ... (5 experiments)
endotoxin
1
E-GEOD-3026
saline
1
E-GEOD-3026
ox-LDL
1
E-GEOD-5741
eicosapentaenoic acid
1
E-MEXP-1389
24 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-GEOD-1140, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-6236, E-MEXP-958, ... (6 experiments)

Dfs follow up
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Erbb2
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-GEOD-2292, E-GEOD-20115, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-20540, E-GEOD-9764, E-GEOD-10315, E-GEOD-4425 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-512, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-MEXP-1403 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19246 ... (5 experiments)

RNAi
studied in E-MEXP-1422, E-GEOD-1676, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Tumor size
studied in E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.331 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM